替米沙坦对原发性高血压心肌肥厚及左室舒张功能的影响

The influence of telmisartan in treatment of hypertrophy and the diastolic function of left ventricular in patients with hypertension

目的：探讨替米沙坦对原发性高血压患者心肌肥厚及左室舒张功能的影响。方法选取我院2013年4月-2014年5月收治的78例原发性高血压并心肌肥厚及左室舒张功能不全患者为研究对象,均给予口服替米沙坦片方案,比对其治疗前后舒张压﹙DBP）、收缩压﹙SBP）变化情况及超声心动图各指标差异,记录其治疗前后心功能分级情况。结果①治疗后,收缩压和舒张压分别为﹙107.6±9.9）mmHg和﹙73.3±5.2）mmHg,较治疗前的﹙153.5±12.6）mmHg和﹙98.9±8.0）mmHg降低,差异有统计学意义﹙P〈0.05）；②治疗后,左心室后壁厚度、室间隔厚度、左心室舒末内径、左室重量指数、舒张晚期二尖瓣口血流速度峰值A等指标均较治疗前明显降低﹙P〈0.05）；舒张早期二尖瓣口血流速度峰值E则显著升高﹙P〈0.05）；③治疗后,Ⅰ级例数由治疗前的24例增加至62例,心功能较治疗前明显改善﹙P〈0.05）。结论对原发性高血压并心肌肥厚及左室舒张功能不全者予以口服替米沙坦方案,疗效显著,值得临床推广。

Objective To investigate the effects of telmisartan in treatment of hypertrophy and diastolic function of left ventricular in patients with hypertension and left ventricular. Methods A total of 78 patients admitted to our hospital with primary hypertension and myocardial hypertrophy and left ventricular diastolic dysfunction from April 2013 to May 2014 were selected as the research objects, and they were given telmisartan tablets orally, the differences of diastolic blood pressure （DBP）, systolic blood pressure （SBP） changes and the ultrasonic heartbeat of each index recorded before and after treatment, recorded the heart function classification as well were compared. Results ①After the treatment, systolic and diastolic blood pressure were （107.6±9.9） mmHg and （73.3±5.2） mmHg, compared with the data of before treatment （153.5±12.6） mmHg and（98.9±8.0） mmHg, decreased significantly and there were statistical differences（P〈0.05）; ②After the treatment, left ventricular posterior wall thickness, index interventricular septum thickness, left ven-tricular end diastolic diameter, left ventricular mass index and late diastolic mitral flow velocity A were significantly lower than that before treatment （P〈0.05）; Early diastolic mitral flow velocity peak E increased significantly （P〈0.05）;③After treatment, the number of grade Ⅰ from 24 patients before treatment increased to 62 cases, cardiac function significantly improved after treatment（P〈0.05）. Conclusion The significant effect on primary hypertension and myocar-dial hypertrophy and left ventricular diastolic dysfunction by oral telmisartan, is worth the clinical promotion.